Cortexyme’s first-day pop leads IPO quartet amid choppy market

How four IPOs helped push YTD tally from public market debuts well ahead of last year’s pace.

Despite unsettled market conditions, a foursome of biotechs priced their IPOs within their proposed ranges ahead of first-day trading Thursday and helped push the year-to-date tally of money raised in public market debuts well ahead of last year’s pace. Coming during a week when escalating trade tensions between the U.S. and China have propelled indexes downward, the offerings will be closely watched by the bolus of companies in the IPO queue.

CNS company Cortexyme

Read the full 732 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE